← Back to Stock Screener← Stock Screener

ZYBERNO

Stock Report

Updated Aug 30, 2026

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Healthcare • NASDAQ

$107.17

Rhythm Pharmaceuticals Inc. is an American biopharmaceutical company headquartered in Boston, Massachusetts, focused on rare genetic diseases of obesity. The company's approved product setmelanotide (Imcivree) is an MC4R pathway agonist for the treatment of obesity caused by certain rare genetic disorders including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome, and its pipeline targets additional melanocortin system obesity disorders.

Professional Investment Analysis

ZYBERNO SCORE →

Is it a great business? Is it getting better?

28.0/100

POOR BUSINESS

RHYTHM PHARMACEUTICALS, INC. (RYTM) scores 28/100 — concerning metrics indicating significant structural or financial risks.

📊 How is the Zyberno Score calculated? +

The Zyberno Score answers one question: "Is this a quality business worth owning?" It's a 0-100 investment grade that evaluates business fundamentals across four critical dimensions, based on principles from Warren Buffett, Benjamin Graham, Peter Lynch, and Charlie Munger.

The 4 Core Categories (25 points each):

1. PROFITABILITY (25 pts)

Metrics: ROE, ROIC, Net Margin, Operating Margin
Thresholds: ROE >20% excellent • ROIC >20% excellent • Net Margin >20% excellent • Operating Margin >25% excellent

2. FINANCIAL STRENGTH (25 pts)

Metrics: Debt-to-Equity, Current Ratio, Interest Coverage, Altman Z-Score
Thresholds: D/E <0.3 excellent • Current Ratio >2.5 excellent • Interest Coverage >10x excellent • Altman Z >3.0 safe

3. CASH FLOW QUALITY (25 pts)

Metrics: Free Cash Flow, OCF vs Net Income, FCF Margin
Thresholds: Positive & growing FCF excellent • OCF/NI >1.2x excellent (cash earnings exceed accounting)

4. GROWTH & CONSISTENCY (25 pts)

Metrics: Revenue Growth, Net Income Growth, FCF Growth, Piotroski F-Score
Thresholds: Growth via log-linear regression • Piotroski 8-9 excellent, 6-7 good

Score Interpretation:

75-100

GREAT BUSINESS

65-74

GOOD BUSINESS

50-64

AVERAGE BUSINESS

30-49

WEAK BUSINESS

0-29

POOR BUSINESS

→ View full RYTM quality analysis & detailed breakdown

VALUATION SIGNAL

N/A (Requires more data)

Requires fair value calculation and current price data

💰 How is Margin of Safety calculated? +

Margin of Safety measures how much discount or premium you're paying relative to a stock's intrinsic value. It's Benjamin Graham's core principle: the larger the margin, the lower your downside risk.

Formula: (Intrinsic Value − Current Price) ÷ Intrinsic Value × 100%

How We Calculate Intrinsic Value (DCF Method):

Step 1: Calculate current Owner Earnings (OCF − Maintenance CapEx)

Step 2: Calculate company-specific growth rate using log-linear regression on 16 quarters of Owner Earnings

Step 3: Project 10 years forward using the calculated growth rate

Step 4: Discount each year's cash flow to present value using 10% discount rate

Step 5: Calculate terminal value using 3% perpetual growth rate

Step 6: Sum all discounted cash flows = Intrinsic Value

What The Percentages Mean:

+50% or more

EXCELLENT — Very undervalued

+25% to +50%

GOOD — Attractive discount

0% to +25%

FAIR — Reasonable value

0% to -25%

CAUTION — Slight premium

-25% or worse

POOR — Overvalued

"Price is what you pay, value is what you get." — Warren Buffett

→ View full RYTM valuation analysis · → View full RYTM Brina Gap analysis

📈 How is Brina Gap calculated? +

Brina Gap measures the difference between the growth a business can fundamentally sustain and the growth the market is already pricing in.

Formula: Fundamental Growth Rate − Market-Implied Growth Rate

The Two Components:

Fundamental Growth Rate = ROIC × Reinvestment Rate

What the business can sustainably grow at based on how much it reinvests and what return it earns on that capital. Grounded in historical financials.

Market-Implied Growth Rate = Reverse DCF

The growth rate the current Enterprise Value implicitly assumes. Calculated by back-solving a 10-year DCF model (10% WACC, 3% terminal growth) until the present value of projected cash flows equals EV.

What The Gap Means:

Gap > +5% Market Underestimates — potential upside

+2% to +5% Slight Underestimate

-2% to +2% Fairly Priced — market consensus matches fundamentals

-5% to -2% Slight Overestimate

Gap < -5% Market Overestimates — price embeds optimism fundamentals don't support

A positive gap (market underestimates) combined with a positive Margin of Safety is the strongest combined signal — the business is both cheap historically and forward economics are stronger than the price suggests.

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-159.9%)

Debt-to-Equity (Solvency Risk):EXCELLENT (0.07x)

Operating Margin (Operational Efficiency):CRITICAL (-83.6%)

Return on Capital (Capital Efficiency):CRITICAL (-141.5%)

📊 Valuation Trilogy

Three interconnected metrics for complete valuation analysis

Click any metric for full methodology and detailed analysis

Zyberno's Verdict

RHYTHM PHARMACEUTICALS, INC. (RYTM) stock report — Zyberno Score 28/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, RYTM generated -$136.21M in Owner Earnings. Capital was deployed as follows: $47.00K invested in capital expenditures. Reinvestment rate: -0.3%.

DIVISION I: EXECUTIVE SUMMARY

A. Market Valuation

Market Price & Capitalization (2)

Current Price:107.17

Market Cap:$7.35B

Valuation Multiples (3)

P/B Ratio:71.38x

P/S Ratio:30.64x

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$7.13B

Price Action & Momentum (3)

12-1 Momentum:

+19.8% (88th pctile)

📈 Click to view full RYTM Momentum analysis →

Momentum Percentile:88 / 100

% of 52-Week High:87.7%

B. Profitability Assessment

Return Metrics (5)

ROE:

-159.9%

📊 Click to view full RYTM ROE analysis →

ROA:-44.0%

Roic:

-141.5%

📊 Click to view full RYTM ROIC analysis →

Reinvestment Rate:-0.3%

Fundamental Growth Rate (g):0.4%

Margin Analysis (3)

Operating Margin Ttm:-83.6%

Net Margin Ttm:-85.6%

Ebitda Margin:-83.3%

TTM Performance (3)

Gross Margin Ttm:89.0%

Operating Margin Ttm:-83.6%

Net Margin Ttm:-85.6%

Yield Metrics (2)

Earnings Yield:-$2.90

Dividend Yield:0.0%

C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

Earnings Surprise (SUE):

+0.05

📊 Click to view full RYTM Earnings Surprise analysis →

EPS Surprise vs Expected:4.3%

Latest Earnings Filed:2026-08-04

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):59.3%

D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.45x

Quick Ratio:3.20x

Cash Ratio:2.68x

Leverage Analysis (3)

Debt To Equity Ttm:0.07x

Debt-to-Equity Ratio:0.07x

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-10.39x

Times Interest Earned:-10.39

Capital Structure (4)

Working Capital:302,976,000.00

Cash And Cash Equivalents:330,900,000.00

Long Term Debt:$93.40M

Net Debt:-$224.80M

DIVISION II: FINANCIAL STATEMENTS ANALYSIS

A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $239.92M

Linear Growth: 59.3%

📊 Click to view full RYTM Revenue analysis & methodology →

Cost Of Revenue Ttm:$26.39M

Profitability Breakdown (2)

Gross profit TTM: $213.53M

Linear Growth: 59.1%

📊 Click to view full RYTM Gross Profit analysis & methodology →

-$200.63M

Bottom Line Performance (3)

-$205.35M

Income Before Tax:-$204.28M

Ebitda Ttm:-199,813,000.00

Operating Expenses (5)

Operating Expenses:440,547,000.00

R And D Expense:173,212,000.00

Sga Expense:240,946,000.00

Income Tax Expense:$1.49M

Interest Expense:18,480,000.00

Expense Ratios (3)

R And D To Revenue Percentage:243.1%

Sga To Revenue Percentage:338.1%

Ebitda Margin:-83.3%

B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$437.27M

Current Assets:$426.56M

Ppe Net:103,000.00

Goodwill:0.00

Intangible Assets:$4.89M

Liability Structure (4)

Total Liabilities:334,283,000.00

Current Liabilities:123,587,000.00

Long Term Debt:$93.40M

Short Term Debt:$12.70M

Equity & Capital (3)

Equity:$102.98M

Retained Earnings:-$1.46B

Common Stock:120,000,000.00

Working Capital Items (3)

Accounts Receivable:40,408,000.00

Inventory:30,517,000.00

Accounts Payable:16,165,000.00

Special Items (2)

Contract Liabilities:0.00

Stock Based Compensation:23,099,000.00

C. Cash Flow Analysis

Operating Activities (2)

-$119.51M-$119.56M

Investment Activities (2)

Investing Cash Flow:$57.05M

Capital Expenditures Ttm:47,000.00

Financing Activities (3)

Financing Cash Flow:-$5.40M

Dividends Paid Ttm:0.00

Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00

Long Term Debt Issuance:$0.00

Long Term Debt Repayments:$4.29M

Non-Cash Items (1)

Depreciation Amortization Ttm:816,000.00

DIVISION III: OPERATIONAL METRICS

A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.11

-$3.11

Earnings Per Share Ttm:-$2.99

Revenue & Cash Per Share (2)

Sales Per Share Ttm:3.50

Operating Cash Flow Per Share:-$1.69

Book Value & Capital (2)

Book Value Per Share:$1.50

Cash Per Share:4.82

Dividend Policy (1)

Dividend Payout Ratio:-999.00x

B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.51x

Working Capital Turnover Ttm:0.79x

Receivables Management (2)

Receivables Turnover Ttm:5.94x

Days Sales Outstanding Ttm:61.47

Inventory Management (2)

Inventory Turnover Ttm:0.86x

Days Inventory Outstanding Ttm:422.10

Payables & Cash Cycle (2)

Days Payable Outstanding:223.59

Cash Conversion Cycle:259.98

C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00

Quality Score:30.00

Market Metrics (2)

Beta:0.00x

Volatility Category:unknown

DIVISION IV: INVESTMENT ANALYSIS

A. Value Investment Framework

Owner Earnings Analysis (1)

-$136.21M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.3%

Fundamental Growth Rate (g):0.4%

B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):59.3%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):59.1%

Book Value Growth Rate (Linear):-26.5%

C. Company Profile & Context

Corporate Information (6)

Symbol:RYTM

Company Name:RHYTHM PHARMACEUTICALS, INC.

Sector:Healthcare

Industry:Pharmaceuticals

Exchange:NASDAQ

Country:United States

Market Classification (3)

Market Cap Category:N/A

Price Category:high

Volume Category:N/A

Share Structure (3)

Shares Outstanding:68.59M

Shares Outstanding Basic:68.59M

Shares Outstanding Diluted:68.59M

Data Processing Info (3)

Processing Version:v3.0

Last Updated:2026-08-30 01:36:35 UTC

Data Timestamp:2026-08-30T01:36:35.394806